Clinical Trial of BT02 in Patients With Advanced Solid Tumors
A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Antitumor Activity of BT02 in Patients with Advanced Solid Tumors
Advanced Solid Tumor
DRUG: BT02 monoclonal antibody injection
Dose Limiting Toxicity, safety, Within day 28 after administration|Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), Safety, Within day 28 after administration|Maximum tolerated dose, Maximum tolerated dose, Within day 28 after administration
The Pharmacokinetics characteristics of BT02, Levels of BT02 in blood, Within day 28 after administration|Progression-free survival (PFS), The time from the date of first study treatment to the first occurrence of disease progression., From date of enrollment until the date of revocation of informed consent, termination from the trial, or initiation of new anti-tumor treatment, loss of follow-up or death, whichever came first, assessed up to 100 months.|Overall survival (OS), The time from the date of first study treatment to death from any cause., From date of enrollment until the date of revocation of informed consent, termination from the trial, or initiation of new anti-tumor treatment, loss of follow-up or death, whichever came first, assessed up to 100 months.|Duration of response, The time from first occurrence of a documented response to disease progression., From date of enrollment until the date of revocation of informed consent, termination from the trial, or initiation of new anti-tumor treatment, loss of follow-up or death, whichever came first, assessed up to 100 months.|Objective Response Rate (ORR), The sum of the proportion of subjects with CR or PR, From date of enrollment until the date of revocation of informed consent, termination from the trial, or initiation of new anti-tumor treatment, loss of follow-up or death, whichever came first, assessed up to 100 months.
Overall study design:

This is an open-label, FIH, Phase I / II study of BT02 to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of BT02 in adult patients with advanced solid tumors.